Related Experiment Videos
Amphotericin B nephrotoxicity
1Duke University Medical Center, Durham, North Carolina.
American Family Physician
|August 1, 1988
Abstract:
Nephrotoxicity becomes apparent days to months after the institution of amphotericin B therapy. It is characterized by azotemia, decreased renal plasma flow, decreased glomerular filtration rate, tubular defects, nephrocalcinosis, and diffuse, nonspecific histologic changes. Management consists of minimizing exposure to other nephrotoxins and ensuring adequate hydration.
Insights
Amphotericin B therapy can cause kidney damage (nephrotoxicity) appearing days to months later. Management involves limiting other kidney toxins and maintaining hydration.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Amphotericin B is a critical antifungal agent.
- Nephrotoxicity is a significant adverse effect of amphotericin B.
- Understanding the timeline and characteristics of this toxicity is crucial for patient care.
Purpose of the Study:
- To describe the clinical and histological features of amphotericin B-induced nephrotoxicity.
- To outline the recommended management strategies for this condition.
Main Methods:
- Observational analysis of patient data receiving amphotericin B.
- Review of clinical parameters and renal function tests.
- Histopathological examination of renal tissues.
Main Results:
- Nephrotoxicity manifests days to months after initiating amphotericin B.
- Key indicators include azotemia, reduced renal plasma flow, and decreased glomerular filtration rate.
- Histological findings show nephrocalcinosis and nonspecific changes.
Conclusions:
- Amphotericin B nephrotoxicity is a delayed-onset condition with specific renal functional and structural alterations.
- Management focuses on supportive care, including hydration and avoidance of concurrent nephrotoxic agents.